The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy - Archive ouverte HAL Access content directly
Journal Articles Current Pharmaceutical Design Year : 2014

The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy

(1) , (1) , , ,
1
P. Maire
  • Function : Author
R. W. Jelliffe
  • Function : Author
M. Neely
  • Function : Author
Not file

Dates and versions

hal-02046812 , version 1 (22-02-2019)

Identifiers

  • HAL Id : hal-02046812 , version 1

Cite

Sylvain Goutelle, Laurent Bourguignon, P. Maire, R. W. Jelliffe, M. Neely. The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. Current Pharmaceutical Design, 2014, 20, pp.6191-6206. ⟨hal-02046812⟩
14 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More